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TGFb overexpression is commonly detected in cancer patients and correlates with poor
prognosis and metastasis. Cancer progression is often associated with an enhanced
recruitment of myeloid-derived cells to the tumor microenvironment. Here we show that
functional TGFb-signaling in myeloid cells is required for metastasis to the lungs and the
liver. Myeloid-specific deletion of Tgfbr2 resulted in reduced spontaneous lung
metastasis, which was associated with a reduction of proinflammatory cytokines in the
metastatic microenvironment. Notably, CD8+ T cell depletion in myeloid-specific Tgfbr2-
deficient mice rescued lung metastasis. Myeloid-specific Tgfbr2-deficiency resulted in
reduced liver metastasis with an almost complete absence of myeloid cells within
metastatic foci. On contrary, an accumulation of Tgfb-responsive myeloid cells was
associated with an increased recruitment of monocytes and granulocytes and higher
proinflammatory cytokine levels in control mice. Monocytic cells isolated from metastatic
livers of Tgfbr2-deficient mice showed increased polarization towards the M1 phenotype,
Tnfa and Il-1b expression, reduced levels of M2 markers and reduced production of
chemokines responsible for myeloid-cell recruitment. No significant differences in Tgfb
levels were observed at metastatic sites of any model. These data demonstrate that Tgfb
signaling in monocytic myeloid cells suppresses CD8+ T cell activity during lung
metastasis, while these cells actively contribute to tumor growth during liver metastasis.
Thus, myeloid cells modulate metastasis through different mechanisms in a tissue-
specific manner.
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The main cause of cancer-related fatalities in patients is metastasis, a multistep process enabling
tumor cells to spread through blood circulation and to form metastasis in distant organs. Stromal
cells such as fibroblasts, endothelial and immune cells are integral parts of both primary tumor and
metastatic lesions (1, 2). Tumor cells together with stromal cells produce cytokines that orchestrateNovember 2021 | Volume 11 | Article 7651511
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cancer progression. The TGFb family of cytokines are directly
linked to tumorigenesis, where they actively promote
tumorigenesis through a modulation of the tumor
microenvironment during metastasis (3–5).
TGFb cytokines are involved in a wide range of biological
processes, such as cell proliferation, differentiation, wound
healing, and immune cell regulation (3). TGFb-signaling is
initiated by binding to TGFb receptor I (TGFbRI), which
recruits and phosphorylates TGFb receptor II (TGFbRII), and
results in activation of: the canonical pathway, involving SMAD
proteins regulating a wide range of genes; and the non-canonical
pathway that includes MAPK and PI3K signaling (4). In the
context of cancer, TGFb1 can act both as a tumor suppressor, in
the early stages of cancer, and as a tumor promoter, in the later
stages of tumor progression. In advanced cancers, however;
TGFb expression and activation strongly correlate with poor
prognosis due to metastasis (4, 6).
TGFb is an immunosuppressive cytokine produced by tumor
cells and immune cells that polarizes both the innate and the
adaptive immune system (7) and represents a primary
mechanism of immune evasion (8). TGFb inhibits NK cell
function by decreasing cytokine production and in dendritic
cells downregulates the expression of MHCII and co-stimulatory
molecules. Within the tumor microenvironment, TGFb
signaling promotes immune suppression of macrophages and
neutrophils, which results in alternatively polarized phenotypes
of M2 and N2, respectively. In the lymphoid compartment,
TGFb dampens the activity of CD4+ T helper and of CD8+
cytotoxic T cells and promotes the activity of regulatory T (Treg)
cells (7).
Myeloid cells promote immune suppression and formation of a
metastatic niche and are abundantly present in cancer patients both
as circulating cells in the blood and in tumor tissues (9–12).
Systemic expansion of immature myeloid cells during cancer
progression can be divided into two subpopulations of
granulocytic (CD11b+/Ly6G+) and monocytic (CD11b+/Ly6Chi)
myeloid-derived suppressor cells (9). In the tumor
microenvironment TGFb is an important factor promoting
immune-suppressive polarization of myeloid-derived cells. Breast
cancer metastasis to the lungs was dependent on myeloid cell
recruitment and formation of pro-tumorigenic microenvironment
(13). Inhibition of Tgfb in tumor bearing-mice resulted in increased
infiltration of cytotoxic CD11b+/Ly6G+-derived neutrophils and
reduced tumor growth (14). Initial studies in mice with Tgfbr2-
deficiency in myeloid cells showed reduced tumor growth, which
was associated with an increased anti-tumor polarization of
macrophages (15). Further studies in Tgfbr2-myeloid cell deficient
mice showed reduced lung metastasis in 4T1 mammary tumor
model (16, 17), which was ascribed to enhanced presence of
cytotoxic CD8+ T cells (16). Tumor-associated myeloid cells
express CCL9 chemokine, which is upregulated in a TGFb-
dependent manner (17). The overexpression of CCL9 in Tgfbr2-
deficient myeloid cells enabled metastasis. In a recent study, the
CXCL1-CXCR2 axis was identified to mediate myeloid cell
recruitment to the pre-metastatic liver (10). However, theFrontiers in Oncology | www.frontiersin.org 2contributing effects of TGFb signaling during liver metastasis
remain unclear.
The current study investigates and compares the tissue-
specific role of TGFb signaling in myeloid cells and its
influence on the metastatic microenvironment in lung and
liver metastasis using a LysMCre/Tgfbr2fl/fl mouse model.MATERIALS AND METHODS
Cell Culture
MC-38GFP murine colon carcinoma cell line (18), LLC1.1 Lewis
lung carcinoma, 3LL lung carcinoma, and B16-BL6 were grown
in DMEM high glucose medium (Life Technologies) containing
10% fetal bovine serum (FBS) as described previously (19).
Mice
LysMCre/Tgfbr2fl/fl mouse in a C57BL/6J background was
obtained from M. Heikewälder (University of Zurich). The
mouse strain ROSA-STOPfl/fl-dTomato was obtained from The
Jackson Laboratory. All mice were in the C57BL76J background.
Both males and female animals in the age of 7-10 weeks of age
were used in all experiments. All animal experiments were
performed according to the guidelines of the Swiss Animal
Protection Law, and approved by the Veterinary Office of
Kanton Zurich.
Metastasis Models
Spontaneous lung metastasis. Lewis lung carcinoma cells LLC1.1
(300,000 cells) were subcutaneously (s.c.) injected into a right
flank of a mouse. The primary tumor was removed after 18 days
and the extent of lung metastasis was evaluated two weeks after
tumor removal. Experimental liver metastasis. MC-38GFP colon
cancer cells (300,000 cells) were injected into the spleen of an
anesthetized mouse. Splenectomy was performed three minutes
after the tumor cell injection. Mice were terminated on day 28
and liver metastasis was evaluated. Experimental lung metastasis.
MC-38GFP (300,000 cells) were intravenously injected and mice
were terminated 28 days after the injection. 3LL and B16-BL6
cells (150,000 cells) were intravenously injected and lungs
analyzed on day 14 (19). Surface metastasis were counted in
perfused lung and liver tissues.
Immunohistochemistry
Tissues paraffin sections (3 mm) were stained with hematoxylin/
eosin or the anti-GFP antibody (Fitzgerald Industries Int.) Ki67
(NeoMarkers) and cleaved caspase-3 (BD). Quantification of
tumor cells in seven sections of lungs separated by 20 mm was
per formed . S ta in ing was per formed on a NEXES
immunohistochemistry robot using an IVIEW DAB Detection
Kit (Ventana Instruments, Switzerland). Images were digitalized
on Zeiss MiraxMidi Slide Scanner and analyzed with Panoramic
Viewer (3DHISTECH). For cryosections, tissues were fixed in 3%
paraformaldehyde for 1 hour at 4°C, incubated in 20% sucrose
overnight at 4°C, embedded in an OCT compound and snap-
frozen in a bath containing methylbutane and dry ice.November 2021 | Volume 11 | Article 765151
Stefanescu et al. Myeloid-Cell TGFb Signaling During MetastasisCryosections (10 mm) were blocked with phosphate buffer
saline (PBS) containing 5% FCS and 5% rat serum, and
incubated with AlexaFluor 647-coupled rat-anti-F4/80
antibody (Clone BM8, Biolegend). Slides were counterstained
with DAPI and embedded in Prolong and evaluated on Leica
Thunder Microscope.
Flow Cytometry Analysis
Mice were perfused with PBS and dissected tissues were minced
and digested with Collagenase A and D (1 mg/mL, both from
Roche), in 2 mL of RPMI medium containing 3% BSA for 1 hour
at 37°C. The cell suspension was prepared by passing the
homogenate five times through 18G needle followed by a
100mm cell strainer. In case of liver, the cell suspension was
centrifuged at 500 rpm for one minute to separate the
parenchyma. After centrifugation of the single cell suspension,
erythrocytes lysed with ACK buffer and cells were passed
through a 70mm cell strainer. The pellet was resuspended in a
FACS buffer (PBS/2% FBS/5mM EDTA) and stained with
Zombie Fixable Viability Kit (Biolegend), followed by
incubation with anti-mouse CD16/32 mAb for 10 min on ice.
Single cell suspensions were stained with the following
antibodies: anti-CD45 (clone 30-F11), anti-CD11b (clone M1/
70), anti-F4/80 (clone BM8), anti-Ly6G (clone 1A8), anti-Ly6C
(clone HK1.4), anti-MHCII (clone M5/114.15.2), anti-CD31
(clone 390), CD4 (clone GK1.5), anti-CD8 (clone 53-6.7) and
anti-PD1 (clone 29F.1A12) (all from Biolegend) for 30 min on
ice. Data was acquired on a FACSCanto II (BD Biosciences),
during cell quantification together with CountBright absolute
counting beads (Life Technologies) and analyzed using Flow Jo
software v. 7.6.5 (Tree Star). Samples for CD8 cell activation
assessment were fixed and permeabilized using FoxP3/
Transcription Factor Staining Buffer Set (eBioscience).
Subsequently samples were stained for intra-cellular markers
with the following antibodies: anti-Granzyme B (clone GB11)
and anti-Perforin (clone S16009A) from Biolegend. CD8 cell
activation was analyzed using the Cytek Aurora 5L – Spectral
Analyzer from the Cytometry Facility at the University of Zurich.
Cell Sorting and Quantitative PCR
Tissues were processed the same way as described for flow
cytometry analysis. Individual cell populations were sorted
using a BD Aria III in FACS buffer at 4°C using a 100 mm
nozzle. From at least 100’000 sorted cells RNA was isolated using
the RNA Easy Plus Mini kit (Qiagen) and cDNA was prepared
using 250 ng of RNA using Omniscript RT kit (Qiagen)
according to the manufacturer’s instructions. Real-time PCR
was performed with KAPA Sybr FAST Universal (Sigma) using
intron-spanning primers (Supplementary Table S1) and
analyzed in a CFX96 Touch Real-Time PCR Detection System
(Biorad). GAPDH was used as an internal control.
Fluorescent Beads Uptake Assay
Red fluorescence beads (Sigma) were diluted 1:20 in PBS and 100
ml was intravenously injected through a tail-vein per mouse.
Mice were terminated after 9 hours, blood and organs were
collected and processed as described in flow cytometry analysis.Frontiers in Oncology | www.frontiersin.org 3Reactive Oxygen Species (ROS)
Determination
Tumor bearing mice (subcutaneous LLC1.1 tumor) were
anesthetized, the lungs perfused with PBS and through heart
perfused with pre-warmed 5 mM CellROX® Oxidative Stress
Green Reagent (Invitrogen) and the vessels clipped. After 30 min
of incubation, the lungs were again perfused with PBS, digested
with collagenase and single cell suspension stained with anti-
Ly6G antibody and the ROS signal was quantified by
flow cytometry.
Tumor Cell In Vivo Seeding Assay
MC-38-luciferase expressing cells (300,000) were injected
through spleen in mice and at indicated time points, mice were
anesthetized, subcutaneously injected with D-luciferin firefly
(150 mg/g mouse) and after 8 min terminated. Mice were
perfused with PBS and the luciferase activity in the liver was
determined using IVIS imaging. After the intravenous injection
of 300,000 MC-38GFP cells mice were terminated at indicated
time points; mice perfused with PBS and lungs processed for
histological analysis.
Antibody Depletion Experiments
Depletion of CD8+ T cells in a lung metastasis model using
LLC1.1 cells was performed with 10 mg anti-CD8 antibody (clone
2.43; BioXCell) i.v. injected one day prior to primary tumor
removal. Mice received another 15 mg of the antibody by i.v.
injection two days after the tumor removal. Control mice
received the isotype control antibody (clone 2A3, BioXCell) in
parallel. In the liver metastasis model, mice received 10 mg Ab
injection 1 day before tumor cell injection and the second
treatment with 15 mg Ab two days after tumor cell injection.
Neutrophil depletion was achieved by intraperitoneal
injection (i.p.) of anti-Ly6G antibody (clone 1A8; BioXCell).
Initial injection of 500 mg/mouse was performed 24 hours prior
to intrasplenic injection of MC-38GFP cells. Mice were treated
three times weekly with 100 mg i.p. until the termination at day
27. Control animals were injected with isotype-control Ab (clone
2A3, BioXCell) in parallel.
Cytokine Analysis
Snap-frozen tissues were homogenized using Polytron® in lysis
buffer (FACS buffer containing 1x complete EDTA free proteinase
inhibitor cocktail from Roche). After 15 min centrifugation at
14’000 rpm at 4°C, was determined the protein concentration in
the supernatant was determined with BCA Protein Assay (Thermo
Fischer). Cytokine concentrations were measured in a total of 200-
500 mg of tissue lysate using the ProcartaPlex 23 Plex and the
LegendPlex Mouse Proinflammatory Chemokine panel (Thermo
Fischer) following the manufacturer’s instructions. TGFb1 was
determined using the TGFb Platinum Elisa (Thermo Fisher),
where samples were activated with 1N HCl for 10 min at RT in a
ratio of sample toHCl 5:1. The reactionwas neutralized using 1 part
of 1NNaOH/0.5MHEPES. Sorted tdT+ Ly6Chi monocytes (20’000
cells/well) from livers of mice at day 14-post-intrasplenic injection
of MC-38GFP cells were stimulated overnight (14 hrs) with PMANovember 2021 | Volume 11 | Article 765151
Stefanescu et al. Myeloid-Cell TGFb Signaling During Metastasis(20 ng/ml), ionomycin (1mg/ml) and LPS (1 mg/ml). Cytokine
production was detected in the supernatant after 14 h stimulation
as described above.RESULTS
Myeloid-Specific Deletion of Tgfbr2
Attenuates Lung and Liver Metastasis
Myeloid cells are the dominant population of immune cells
associated with metastatic progression (20–22); and TGFb is an
immunosuppressive cytokine family that promotes metastases
through modulations of the tumor microenvironment (7). To
assess the role of Tgfb-signaling in myeloid cells during lung and
liver metastasis, we generated a mouse with myeloid cell-specific
deletion ofTGFb receptor II (LysMCre+/Tgfbr2fl/flmouse, hereafter
TR2myKO) by crossing the Tgfbr2fl/fl mouse with a mouse
expressing Cre under the control of the Lysozyme promoter
(LysMCre). LysMCreneg/Tgfbr2fl/fl (hereafter Ctrl) served as
a control.
First, we tested the role of myeloid cell-derived Tgfb-signaling
during liver metastasis. We used an experimental liver metastasis
model, where MC-38 murine colon carcinoma cells stably
expressing GFP (MC-38GFP) were injected into the spleen.
Significant reduction of metastatic foci and liver-body mass
ratio was observed in TR2myKO mice when compared to Ctrl
mice (Figure 1A). The size of liver metastatic lesions was also
significantly reduced in TR2myKO mice (Figure 1B). To test
whether myeloid cells affect tumor cell seeding to the liver in a
Tgfb-dependent manner, we intrasplenically injected MC-38-
luciferase expressing cells and analyzed livers 9 and 24 hours
post-tumor cell-injection using bioluminescence imaging
(Figure 1C). No difference in tumor cell detection in the liver
was observed between TR2myKO and Ctrl mice, indicating that
Tgfb-signaling pathway in myeloid cells is not affecting initial
tissue colonization.
Second, we tested whether Tgfb-signaling deficiency inmyeloid
cells affects lungmetastasis. Myeloid cells were previously shown to
promote metastatic seeding to the lungs (22–24). Using three
different cell lines, MC-38, Lewis lung carcinoma 3LL and B16-
Bl6melanoma inexperimental lungmetastasismodels,weobserved
reduced metastasis in TR2myKO mice (Figure 1D and
Supplementary Figures 1A, B). To assess the effect of myeloid
Tgfb-deficiency on lung metastasis, we analyzed tissues sections
two, four and seven days post-tumor cell injection. While the
number of single tumor cells was similar in TR2myeloKO and Ctrl
mice at every time point, we observed a significant reduction of
small clusters (2-10 tumor cells) and large cluster (more than 10
tumor cells) at day 4 and day 7 post-tumor cell challenge in
TR2myKO mice (Figure 1E). These findings indicate that the
metastatic outgrowth in TR2myKO mice has been greatly
hampered (2-10 cells foci) or impaired (>10 cells foci). Next, we
used the spontaneous lung metastasis model, where mice were
subcutaneously (s.c.) injected with Lewis lung carcinoma (LLC1.1)
cells. At day 18 the primary tumorwas surgically removed and after
another 14 days lung metastasis was analyzed. While no differenceFrontiers in Oncology | www.frontiersin.org 4in the primary tumor growth between TR2myKOandCtrlmicewas
observed (Supplementary Figure 1C), a significant reduction of
lung metastasis was detected in TR2myKO mice (Figure 1F).
Increased Presence of Tgfb-Responsive
Myeloid Cells During Liver Metastasis
To understand the role of myeloid cell Tgfb-signaling during
liver metastasis, we analyzed these cells in metastatic livers at two
different time points after tumor cell injection: 14 days –
microscopic metastasis, 28 days – macroscopic metastasis, and
compared the changes to naïve mice. We observed increased
numbers of inflammatory monocytes (Ly6Chi) and neutrophils
(Ly6G+) in Ctrl mice, which were significantly reduced in
TR2myKO at day 28 (Figure 2A). There were no changes in
lymphoid CD4+ or CD8+ cells at any time point. Next, we
analyzed cytokine levels in metastatic livers (Figure 2B).
Increased levels of Ccl2, Ccl7, Cxcl1, and Cxcl10 chemokines
both at day 14 and at day 28 in Ctrl mice correlated well with
respective increased cytokine levels (Figure 2C). Both lower
levels of cytokines and reduced myeloid cell number were
detected in TR2myKO mice. Increased amounts of Tgfb1
cytokine were detected in metastatic livers at day 14,
irrespective of mouse genotype, which decreased to levels
observed in naïve mice at day 28 (Figure 2D).
Next, we aimed to detect myeloid cells in liver metastatic lesions.
We prepared a mouse by breeding of LysMCre+/Tgfbr2fl/fl strain
into a transgenic mouse, Ai14, carrying loxP-flanked STOP cassette
followed by tdTomato inserted into the ROSA26 locus. We
analyzed myeloid cells from naïve LysMCre+/Tgfbr2fl/fl/tdT+ mice
(TR2myKO/tdT) and LysMCre/Tgfbr2wt/tdT+, wild-type allele (Ctrl/
tdT) mice, and detected over 90% tdT+ Ly6G+ and over 30% tdT+ of
Ly6Chi cells in liver, lungs and spleen (Supplementary Figure 2).
When MC-38GFP tumor cells were injected intrasplenically into
TR2myKO/tdT and Ctrl/tdT mice, we observed increased numbers
of both Ly6Chi and Ly6G+ cells in Ctrl/tdT mice by flow cytometry,
while in TR2myKO/tdTmice thesemyeloid cells were hardly present
in the metastatic lesions (Figure 3A). These results confirm our
previous data (Figure 2A). The histological analysis of liver sections
at day 14 and 28 days post-tumor cell injection substantiated the
finding of a pronounced reduction of tdT-positive cells within
metastatic foci in TR2myKO/tdT when compared to Ctrl/tdT mice
(Figure 3B). Furthermore, large proportion of tdT-positive cells
were positive for an F4/80 antigen (Figure 3C), indicating
differentiation of myeloid-derived cells into macrophages.
Histological analysis of metastatic livers for proliferating cells
(Ki67+ cells) and for apoptotic cells (cleave-caspase3+ cells)
revealed no obvious differences between Ctrl and TR2myKO mice
(Supplementary Figure 3). These data show a reduced presence of
Tgfb-responsive myeloid cells inside the growing metastatic foci,
which correlated with decreased amounts of chemokines in the
metastatic livers in TR2myKO mice.
Tgfb-Mediated Polarization of Monocytic
Myeloid Cells Promotes Liver Metastasis
To assess how Tgfb-responsive myeloid cells promote liver
metastasis, we first analyzed myeloid cells from metastaticNovember 2021 | Volume 11 | Article 765151
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myeloid-derived (CD11b+) cells was tested. We analyzed Ly6C+
monocytes and Ly6Glo/Ly6C- macrophages isolated from livers
of mice intrasplenically injected with MC-38 cells at day 14,
during early metastasis. No differences in phagocytic capacity of
monocytic cells were observed between the respective mouse
genotypes (Figure 4A). A recent study using a murine breast
cancer model with 4T1 tumor cells in LysMCre+/Tgfbr2fl/fl miceFrontiers in Oncology | www.frontiersin.org 5showed that CD8+ T cells control lung metastasis (16). Thus, we
depleted CD8+ T cells to test whether myeloid cells modulate
CD8+ T cells and thereby promote liver metastasis. While
efficient depletion of CD8+ T cells in the blood liver and lungs
has been achieved (Supplementary Figure 4A), no effect on liver
metastasis has been observed (Figure 4B). This finding points to
a different mechanism of Tgfb-stimulated pro-metastatic





FIGURE 1 | Attenuation of liver and lung metastases in mice with myeloid cell-deletion of Tgfbr2. (A) Macroscopic quantification of liver metastatic foci and the ratio
of liver weight to the total body mass (%) in TR2myKO and control (Ctrl) mice 28 days after the intraspenic injection of MC-38GFP cells. (B) Representative
macroscopic liver images and hematoxylin/eosin (H&E) stained liver sections indicating liver metastasis. Dotted line represents the edge of metastatic foci (middle
panel). Bar = 500 mm; bar zoom-in = 200 mm. (C) Liver seeding of MC-38 luciferase-expressing cells determined at 9 and 24 hours post-intrasplenic injection of MC-
38 luciferase cells using quantification of luciferase signal in the perfused liver. (D) Macroscopic quantification of lung metastasis in TR2myKO compared to control
(ctrl) mice 30 days after intravenous injection of MC-38GFP cells. Representative images (right panel) of pulmonary metastasis stained with anti-GFP antibodies
(brown). Bar = 1 mm. (E) Quantification of GFP+ cells in lung sections at 2, 4 and 7 days post-tumor cell injection as tumor cell clusters divided into: 1 cell, 2-10 cell
foci and >10 cell foci. Representative images of lung sections from day 4 and 7 stained for GFP (brown). n = 4-6 mice per time point and genotype. Bar = 50 mm.
(F) Spontaneous lung metastasis of LLC1.1 cells subcutaneously injected in TR2myeloKO and Ctrl mice terminated at days 32. Representative H&E stained lung
sections of respective genotype. Bar = 1 mm. For panels (A–D, F) each dot represents a mouse. Statistical significance was assessed using Mann-Whitney t-test:
ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.November 2021 | Volume 11 | Article 765151
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we depleted Ly6G+ cells during experimental liver metastasis.
Depletion of neutrophils showed no difference in liver metastasis
neither in Ctrl nor in TR2myKOmice (Figure 4C), suggesting the
involvement of myeloid-derived monocytic cells.
The altered polarization of monocytes/macrophages and
neutrophils towards M2 and N2 phenotype, respectively, was
previously associated with cancer progression (25, 26).
Therefore, we sorted Ly6Chi monocytes and Ly6G+ neutrophils
from metastatic livers of TR2myKO and Ctrl mice and analyzed
the gene expression associated with M1 and M2 polarization (27)Frontiers in Oncology | www.frontiersin.org 6and N1 and N2 polarization (28), respectively. We observed an
increased expression in seven out of eight genes in monocytic
cells from TR2myKO mice, which were mostly M1 genes
(Figure 4D). Specifically, increased expression of ICAM1,
TNFa and SOCS3, and decreased expression of M2 genes,
CCL2 and Arg1 was detected in Ly6Chi cells from TR2myKO
mice (Figure 4D). However, we observed no significant changes
in polarization of Ly6G+ cells, while only the ICAM1 was
increased in cells from TR2myKO mice. To confirm the altered
polarization of monocytes, we sorted Ly6Chi cells from




FIGURE 2 | Analysis of liver metastasis in Tgfbr2-myeloid cell-deficient mice. (A) Flow cytometry analysis of Ly6Chi, Ly6G+ myeloid-derived cells and CD4+ and
CD8+ lymphocytes in livers of TR2myKO and Ctrl mice upon intrasplenic injection of MC-38GFP cells that were terminated at day 14 or 28, respectively; and
compared to naïve mice. (B) Determination of cytokine amounts in the perfused liver homogenates of TR2myKO and Ctrl mice at day 14 and 28 post-intrasplenic
injection with MC-38GFP cells. (C) Quantification of selected cytokines amounts with significant changes among TR2myKO and Ctrl mice samples. (D) Tgfb1 levels in
the liver of mice after intrasplenic injection of MC-38GFP cells 14 and 28 days post-injection when compared to naïve mice without any tumor cell injection. Statistical
significance was assessed using Mann-Whitney test: ns, not significant; *p < 0.05; **p < 0.01.November 2021 | Volume 11 | Article 765151
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production of Il-1b, and partially increased Tnfa levels when
compared to monocytes from Ctrl mice. Reduced levels of several
cytokines, such as Il-6, Ccl2, Ccl3, Ccl5, Cxcl1 and Cxcl10, but
also Il-10 were detected in Ly6Chi cells from TR2myKO mice
(Figure 4E and Supplementary Figure 4B). Changes in cytokine
production in Ly6Chi cells supports the active role of Tgfb-
signaling in modulation of myeloid-derived cells that facilitates
liver metastasis.
Unchanged Levels of Myeloid Cells
During Lung Metastasis
We studied how the absence of Tgfb-signaling in myeloid cells
reduces lung metastasis. The cellular composition of metastatic
lungs in the LLC1.1 spontaneous metastatic model was analyzed.
We selected day 21, which is 5 days after the primary tumor
removal, as an early metastatic time point; and day 32, as a late
metastatic phase. No differences in the presence of Ly6ChiFrontiers in Oncology | www.frontiersin.org 7monocytes, Ly6G+ granulocytes and CD4+ T cells were detected
between TR2myKO and Ctrl mice at any time point (Figure 5A).
However, we observed increased numbers of CD8+ T cells in the
lungs of TR2myKO mice at day 32 (Figure 5A). Of note, reduced
numbers of F4/80+ macrophages was observed in the lungs of
TR2myKO mice at day 21, but not at day 32, when compared to
control mice (Supplementary Figure 5A). Next, we analyzed
cytokine levels in metastatic lungs at day 21 (Figure 5B). There
was an overall decrease in cytokines in TR2myKO mice when
compared to Ctrl mice, specifically a significant reduction of Ifng,
Il-4, Il-5,Ccl2 and Ccl11 was observed. Since tumor-associated
myeloid cells can inhibit immune cell functions (20), the observed
decrease in Il-4 and Il-5 together with a tendency of Il-10 in
TR2myKOmice suggests a possible reduced polarization of T cells.
The reduced Ccl2 levels detected in TR2myKO mice corresponds
well with reduced macrophages in the lungs. Finally, we measured
the amounts of Tgfb1 cytokine in the lungs of tumor-bearing mice
and compared them with non-injected (naïve) mice (Figure 5C).A B
C
FIGURE 3 | Reduced myeloid cell recruitment to liver metastatic foci in Tgfbr2-myeloid cell-deficient mice. Analysis of tdTomato reporter expression in TR2myKO
(LysMCre+/Tgfbr2fl/fl/tdT+) and Ctrl mice (LysMCre+/Tgfbr2wt/tdT+). (A) Flow cytometry analysis of tdT-positive Ly6Chi and Ly6G+ myeloid cells in perfused livers from
TR2myKO and Ctrl mice at day 28 post-intrasplenic tumor cell injection compared to non-injected mice (naïve). (B) Representative images of metastatic liver foci at
day 14 and 28 post-tumor cell injection in TR2myKO and Ctrl mice showing tumor cells (green), and myeloid cells (red) and counterstained with DAPI (blue). Bar = 30
mm. (C) Immunofluorescence analysis of F4/80-stained macrophages in livers 28 days after MC-38GFP splenic injection in Ctrl mice. Dotted line represents the edge
of a metastatic focus (left panel); tdTomato channel and F4/80 staining (right panel) Bar = 50 mm. Statistical significance was assessed using Mann-Whitney test:
*p < 0.05; **p < 0.01.November 2021 | Volume 11 | Article 765151
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bearing mice at day 14, while at day 28 there was no difference
when compared to the lungs of naïve mice. When we
analyzed metastatic lungs from TR2myKO/tdT and Ctrl/tdT
mice at day 32 days after LLC1.1 s.c. injection, we observed no
changes in the presence of tdT-positive Ly6Chi and Ly6G+ cells
between mouse phenotypes as determined by flow cytometry
(Supplementary Figure 5B).Lung Metastasis Are Controlled Through
Tgfb-Myeloid Cell Suppression of
CD8+ T Cells
Next, we tested whether attenuated lung metastasis is associated
with altered polarization of Tgfb-signaling deficient myeloid
cells, when no major changes in myeloid cell presence in lungsFrontiers in Oncology | www.frontiersin.org 8of TR2myKO/tdT and Ctrl/tdT mice were detected (Figure 5A).
First, the phagocytic activity of myeloid-derived (CD11b+) cells
was tested. We analyzed Ly6C+ monocytes and Ly6Glo/Ly6C-
macrophages isolated from lungs of mice injected with LLC1.1
cells at day 21, during early metastasis. No changes in uptake of
beads neither in monocytic cells nor myeloid-derived
macrophages isolated from TR2myKO and Ctrl mice could be
detected (Figure 6A). Second, we tested the production of
reactive oxygen species (ROS) by myeloid-derived Ly6G+ cells,
which was similar in both mouse genotypes (Figure 6B). These
data indicate no functional changes in Tgfbr2-deficient myeloid
cells in metastatic sites. TGFb signaling is a critical mediator of
immune cell polarization (7). Therefore, we sorted Ly6Chi
monocytes and Ly6G+ neutrophils from the lungs at day 21,
early metastasis, and analyzed their polarization status on a




FIGURE 4 | Altered polarization of Tgfbr2-deficient monocytic cells resulted in reduced liver metastasis. Characterization of myeloid cells from TR2myKO and Ctrl mice at
day 14 post-intrasplenic injection of MC-38GFP cells. (A) The phagocytic capacity of Ly6Chi monocytes and Ly6Clo/Ly6G- macrophages isolated from metastatic livers 9
hours after the intravenous injection of fluorescent beads. (B) Liver metastasis of MC-38GFP cells upon anti-CD8 antibody or isotype control depletion in TR2myKO and
Ctrl mice. Mice were terminated at day 28 and liver metastasis quantified. (C) Liver metastasis of MC-38GFP cells upon anti-Ly6G (1A8) antibody or isotype control
depletion in TR2myKO and Ctrl mice. Mice were terminated at day 28, and liver metastasis quantified. (D) Gene expression analysis of Ly6Chi/tdT+ monocytes and Ly6G+/
tdT+ neutrophils sorted from livers of tdT-reporter TR2myKO and Ctrl mice at day 14 post-tumor cell injection performed by qPCR. A panel of genes associated with M1
and M2 macrophage polarization and N1 and N2 neutrophil polarization was analyzed. (E) Analysis of cytokine production by tdT+ sorted Ly6Chi monocytes from livers of
TR2myKO and Ctrl mice 14 days post-intrasplenic injection of MC-38GFP cells. Cells were stimulated overnight and secreted cytokines were measured in supernatants.
Statistical significance was assessed using Mann-Whitney test: ns, not significant; *p < 0.05; **p < 0.01.November 2021 | Volume 11 | Article 765151
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patterns of myeloid cells (Figure 6C). Since we observed
enhanced infiltration of lungs metastasis with CD8+ T cells in
TR2myKO mice (Figure 5A), we tested their role in control of
lung metastasis. Depletion of CD8+ T cells in a LLC1.1 model 24
h before the primary tumor removal and during the metastatic
phase resulted in increased lung metastasis in TR2myKO mice to
similar levels as observed in Ctrl mice (Figure 6D), indicating
that Tgfb-signaling-deficient myeloid cells control lung
metastasis through modulation of CD8+ T cells. The analysis
of CD8+ T cells frommetastatic lungs (Supplementary Figure 6)
showed a significantly increased levels of perforin+ CD8+ T cells
in TR2myKO mice when compared to Ctrl mice (Figure 6E).
However, no major differences in granzyme B expression, norFrontiers in Oncology | www.frontiersin.org 9alteration in PD1 expression has been observed. These data
provide evidence that the absence of Tgfb-signaling in myeloid
cells results in increased levels of functional CD8+ T cells, which
control metastatic outgrowth in the lungs.DISCUSSION
Cytokines have a key role in orchestrating the tumor
microenvironment both during tumorigenesis and metastasis (29).
TGFb signaling affects primarily the immune compartment of a
tumor and stimulates immune suppressive polarization of myeloid-
derived cells (3). The abrogation of TGFb signaling in mammary
carcinoma resulted in an increased chemokine production;A
B
C
FIGURE 5 | Analysis of spontaneous lung metastasis in Tgfbr2-myeloid cell-deficient mice. (A) Flow cytometry analysis of the myeloid cells, Ly6Chi, Ly6G+; and
lymphocytes, CD4+ and CD8+ cells in lungs at day 21 and 32 after the subcutaneous injection of LLC1.1 cells in TR2myeloKO mice and Ctrl mice, respectively.
(B) Determination of cytokine amounts in the perfused lung homogenates of TR2myKO and Ctrl mice at day 21. Quantification of selected cytokines amounts
(panels) with significant changes among TR2myKO and Ctrl mice samples. (C) Tgfb1 levels in the lungs of tumor-bearing mice at day 14 and 28 after subcutaneous
injection of LLC1.1 cells, when compared to naïve mice. Statistical significance was assessed using Mann-Whitney test: ns, not significant; *p < 0.05; ***p < 0.001.November 2021 | Volume 11 | Article 765151
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On contrary, the absence of Tgfb signaling in myeloid cells
attenuated lung metastasis in a murine mammary tumor model
(16, 22). Here we confirmed that functional TGFb signaling in the
myeloid compartment is essential for lung metastasis and provided
the first evidence for its involvement also in liver metastasis.
The tumor microenvironment varies between primary
tumors and metastatic sites and the composition dynamically
changes throughout cancer progression (1, 30, 31). Therefore, we
analyzed composition of metastatic lungs and livers for the
presence of myeloid cells both in early metastatic phase and in
fully developed metastasis. A strong infiltration of tdTomato-
positive myeloid cells was observed in metastatic liver foci of Ctrl
mice. However, in the very few metastatic foci detected in
TR2myKO mice, we observed virtually no tdT+ cells, indicating
that myeloid cells with non-functional TGFb signaling areFrontiers in Oncology | www.frontiersin.org 10unable either to get recruited or to survive in the liver
metastatic niche. Closer analysis of liver metastasis, revealed
that the majority of tdT+ monocytic cells differentiate into
macrophages (F4/80+ cells).
In a colon cancer mouse model, myeloid cells were shown to
promote liver metastasis (10). Tumor cell-triggered increased
production of CXCL1 by tumor-associated macrophages resulted
in increased myeloid cell recruitment to the premetastatic liver
tissue. In agreement with these data, we observed reduced levels
of CXCL1, CXCL10 but also CCL2, CCL3 and CCL5 in
monocytes (Ly6C+ cells) from metastatic livers of TR2myKO,
with reduced liver metastasis, when compared with Ctrl mice.
Importantly, an overall reduction of chemokines responsible for
recruitment of myeloid cells was observed in TR2myKOmice that
correlated with a minimal number of myeloid cells, both
monocytic and granulocytic, in liver metastatic foci. SinceA B D
E
C
FIGURE 6 | Lung metastasis in Tgfbr2-myeloid cell-deficient mice are controlled by CD8 cells. Characterization of myeloid cells from TR2myKO and Ctrl mice at day
21 (early metastatic lungs) post-subcutaneous injection of LLC1.1 cells. (A) The phagocytic capacity of Ly6Chi monocytes and Ly6Clo/Ly6G- macrophages isolated
from metastatic lungs 9 hours after the intravenous injection of fluorescent beads. (B) Reactive oxygen species (ROS) levels in neutrophils isolated from the lungs of
mice perfused with the CellROX® dye in vivo. Data are presented in median fluorescent intensity (MFI). (C) Gene expression analysis of Ly6Chi/tdT+ monocytes and
Ly6G+/tdT+ neutrophils sorted from metastasis lungs of tdT-reporter TR2myKO and Ctrl mice at day 21 post-tumor cell injection and 5 days after the tumor removal
performed by qPCR. A panel of genes associated with M1 and M2 macrophage polarization and N1 and N2 neutrophil polarization was analyzed. (D) Spontaneous
lung metastasis of LLC1.1 cells upon anti-CD8 antibody or isotype control depletion in TR2myKO and Ctrl mice. Mice were terminated at day 32, and lung metastasis
quantified. (E) Analysis of effector CD8+ cells from metastatic lungs at day 32 in a spontaneous lung metastasis model LLC1.1 using flow cytometry analysis for
detection of perforin, granzyme B and PD-1. Statistical significance was assessed using Mann-Whitney test: ns, not significant; *p < 0.05; **p < 0.01.November 2021 | Volume 11 | Article 765151
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presence of monocytic myeloid cells is expected to modulate
this process. Tgfb-signaling deficiency in myeloid cells resulted
in increased anti-tumorigenic polarization, associated with
increased TNFa and decreased IL-6 production in
subcutaneous mammary and lung tumors (15). In a mammary
tumor model, increased production of Il-6 was shown to be
responsible for myeloid cel l recruitment to tumor
microenvironment (11). Likewise, we observed reduced
production of Il-6 and increased expression levels of TNFa in
monocytic cells from livers of TR2myKO mice. High levels of
pro-inflammatory chemokines, e.g. CCL2 and CCL5, in
circulation are associated with poor prognosis for cancer
patients (32, 33). Particularly, CCL2 is an apparent key
immunosuppressive cytokine in tumors (34). We observed a
strong shift in polarization of monocytic myeloid cells in
TR2myKO mice, associated with reduced expression of CCL2,
CCL3, and CCL5 that was confirmed on both transcription and
protein levels.
Attenuation of lung metastasis observed in a mammary
mouse model of Tgfbr2-deficient myeloid cells was associated
with decreased production of type II cytokines, Tgfb1 and Ccl2
(16, 22). We observed similar reduction in Ccl2 amounts in
metastatic lungs. Interestingly, reduced amounts of Ccl11, Il-4
and Il-5 were also detected, which is in agreement with reduced
alternative polarization of immune cells. Myeloid cell
recruitment to the lungs during mammary carcinoma
metastasis resulted in a decreased IFN-g production and
increase proinflammatory cytokines (13). The gene expression
analysis of sorted monocytes (Ly6C+) and neutrophils (Ly6G+)
showed small differences in inflammatory genes between
TR2myKO and Ctrl mice. Finally, we provide evidence that
spontaneous lung metastasis of LLC1.1 cells is controlled by
CD8+ T cells in TR2myKO mice.
The functional Tgfb signaling in myeloid cells promotes lung
metastasis of mammary tumors through immunosuppression
(16, 22). We detected no significant difference in Tgfb levels in
metastatic lungs nor livers between TR2myKO and Ctrl mice.
However, the increased Tgfb amounts during early metastasis
suggests that Tgfb affects this phase of the metastatic process.
Both tumor cell lines, LLC1.1 and MC-38, produce significant
amounts of Tgfb1 (Supplementary Figure 7). Interestingly,
MC-38 tumor cells deficient in Tgfb1 production produced no
experimental metastasis irrespective of target tissue (data not
shown). Thus, tumor-derived Tgfb appears to be essential during
the early stages of metastasis. How other cells in the metastatic
microenvironment, such as fibroblasts, contribute to Tgfb levels
and thereby metastasis requires further investigation.
Taken together, these data indicate that TGFb modulates
monocytic myeloid cells, and thereby promotes metastasis both
in the lungs and the liver. While the function of myeloid cells
during lung metastasis results in suppression of CD8+ T cells,
myeloid cells seems to contribute directly to liver metastasis. One
caveat of this study is the use of the experimental liver metastasis
model. Nevertheless, we observed pronounced differences in
myeloid cell infiltration in liver metastatic foci, which wasFrontiers in Oncology | www.frontiersin.org 11dependent on a functional Tgfb-signaling in myeloid cells.
Recently, the inefficacy of immunotherapy on liver metastasis
was linked to the macrophage-assisted elimination of T cells (35),
which indicates an involvement of macrophages in liver
metastasis. Our findings demonstrate that monocytic myeloid
cell infiltration of the liver directly contributes to tumor growth
during liver metastasis. Further studies will show whether
targeting of TGFb-signaling during metastasis may lead to
therapeutic application in cancer patients.DATA AVAILABILITY STATEMENT
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